Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ribociclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 14/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 4/20 | 1.00 |
| ▸ | CCND1 | P24385 | 8/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | CCND3 | P30281 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
| ▸ | CDK16 | Q00536 | 1/20 | 1.00 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 1/20 | 1.00 |
| ▸ | CAMK2D | Q13557 | 1/20 | 1.00 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 1.00 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 3/20 | 0.95 |
| ▸ | CCND2 | P30279 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribociclib SCHEMBL29912679 | 1.00 | CDK4 (1.00) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL29385337 | 1.00 | CDK4 (1.00) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL302310 | 1.00 | CDK4 (1.00) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL29390270 | 0.99 | CDK4 (0.98) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL1998188 | 0.99 | CDK4 (0.98) | CDK4CCND1CDK6CDK2CCND3 | |
| SCHEMBL31607940 | 0.98 | CDK4 (0.97) | CDK4CCND1CDK6CDK2CCND3 | |
| SCHEMBL1993460 | 0.98 | CDK2 (1.00) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL29414075 | 0.95 | CDK4 (0.91) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL2684999 | 0.95 | CDK4 (0.91) | CDK4CCND1CDK6CDK2CCND3 | |
| SCHEMBL31607869 | 0.95 | CDK4 (0.91) | CDK4CCND1CDK6CDK2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319032-A1 | PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB | NOVARTIS FARMACEVTSKA PROIZVODNJA D.O.O. (SI) | 2025-10-16 | — | — | US | claimed |
| EP-4620458-A2 | RIBOCICLIB TABLET | Novartis AG (CH) | 2025-09-24 | — | — | EP | claimed |
| US-20250090531-A1 | Ribociclib Tablet | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | claimed |
| EP-4197530-A1 | RIBOCICLIB TABLET | Novartis AG (CH) | 2023-06-21 | — | — | EP | claimed |
| CN-115554257-A | Ribociclib tablet | 诺华股份有限公司 | 2023-01-03 | — | — | CN | claimed |
| EP-4081518-A1 | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR TREATING CANCER | Accutar Biotechnology, Inc. (US) | 2022-11-02 | — | — | EP | claimed |
| CN-109311876-B | Heteroaryl estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2022-05-03 | — | — | CN | claimed |
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| EP-4730355-A1 | TYPING SYSTEM AND METHOD FOR HR-POSITIVE/HER2-NEGATIVE BREAST CANCER | Lumitype Medical (Huzhou) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| EP-4313987-B1 | PROCESS FOR THE PREPARATION OF RIBOCICLIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRKA D D NOVO MESTO (SI) | 2026-01-14 | — | — | EP | disclosed |
| EP-4676540-A1 | PANRAS INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| US-20220144798-A1 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972649-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| CN-114245753-A | Combination of an anti-HER 2 antibody and a CDK inhibitor for tumor therapy | 江苏康宁杰瑞生物制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| WO-2022029798-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIBOCICLIB | NATCO PHARMA LIMITED (IN) | 2022-02-10 | — | — | WO | disclosed |
| US-20220041598-A1 | RIBOCICLIB SALTS AND SOLID STATE FORMS THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | CDK4 1825/4885CDK6 792/4885CCND1 844/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | CDK4 2202/4885CDK6 2133/4885CCND1 2346/4885 |
| US-20220144798-A1 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, RXFP3, NPY2R | CDK4 1796/4885CDK6 1471/4885CCND1 589/4885 |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | RXFP3, AVPR2, RXFP1 | CDK4 1608/4885CDK6 1958/4885CCND1 1185/4885 |
| US-20220041598-A1 | RIBOCICLIB SALTS AND SOLID STATE FORMS THEREOF | RTCB, KRAS, RRM2B | CDK4 11/4885CDK6 108/4885CCND1 567/4885 |
| US-20250090531-A1 | Ribociclib Tablet | KRAS, NRAS, PIM2 | CDK4 649/4885CDK6 248/4885CCND1 227/4885 |
| US-20250319032-A1 | PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB | NRAS, NSUN2, RTCB | CDK4 205/4885CDK6 188/4885CCND1 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.